How has been the historical performance of Influx Health.?

Influx Health showed positive financial performance from March 2024 to March 2025, with net sales increasing from 99.97 Cr to 104.85 Cr, operating profit rising from 16.96 Cr to 20.56 Cr, and profit after tax growing from 11.13 Cr to 13.37 Cr, despite a decrease in cash flow from operating activities. Total assets and liabilities both grew significantly, indicating balanced growth.

Answer:<BR>The historical performance of Influx Health shows a positive trend in key financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Influx Health's net sales increased from 99.97 Cr in March 2024 to 104.85 Cr in March 2025, reflecting a growth in total operating income from 99.97 Cr to 104.85 Cr. The raw material cost decreased slightly from 65.27 Cr to 63.41 Cr, while employee costs rose from 7.04 Cr to 8.79 Cr. Total expenditure, excluding depreciation, increased from 83.01 Cr to 84.29 Cr. Operating profit (PBDIT) rose from 16.96 Cr to 20.56 Cr, leading to an operating profit margin improvement from 16.97% to 19.61%. Profit before tax also increased from 14.93 Cr to 17.88 Cr, with profit after tax rising from 11.13 Cr to 13.37 Cr, resulting in a PAT margin increase from 11.13% to 12.75%. The company's total assets grew significantly from 40.82 Cr to 70.12 Cr, while total liabilities increased from 40.82 Cr to 70.12 Cr, indicating a balanced growth in both assets and liabilities. Cash flow from operating activities decreased from 8.00 Cr to 7.00 Cr, contributing to a net cash outflow of 1.00 Cr in March 2025, compared to no outflow in the previous year. Overall, Influx Health demonstrated a strong performance with improvements in profitability and asset growth.

Is Influx Health. overvalued or undervalued?

As of December 3, 2025, Influx Health is fairly valued with a PE ratio of 40.22, an EV to EBITDA of 24.18, and a ROCE of 33.05%, positioning it between peers Sun Pharma and Divi's Lab in terms of valuation.

As of 3 December 2025, Influx Health has moved from an attractive to a fair valuation grade. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 40.22, an EV to EBITDA of 24.18, and a ROCE of 33.05%. <BR><BR>In comparison to peers, Influx Health's PE ratio is higher than Sun Pharma's 37.51 and significantly lower than Divi's Lab's 68.92, which is categorized as very expensive. While the company has shown strong returns over the past week and month, outperforming the Sensex, its current valuation suggests that it is neither undervalued nor overvalued in the current market context.

Which are the latest news on Influx Health.?

Why is Influx Health. falling/rising?

As of 04-Dec, Influx Healthtech Ltd's stock price is rising to 242.05, reflecting a 4.99% increase. The stock has outperformed the sector and reached new highs, indicating strong investor interest, although a decline in delivery volume may raise concerns about sustained momentum.

As of 04-Dec, Influx Healthtech Ltd's stock price is rising, currently at 242.05, which reflects an increase of 11.5 or 4.99%. This upward movement is supported by several factors. Firstly, the stock has outperformed the sector by 4.7% today, indicating strong relative performance. Additionally, it has reached a new 52-week and all-time high of Rs. 242.05, which often attracts more investor interest and confidence.<BR><BR>Moreover, the stock has shown significant positive returns over the past week, with a rise of 6.28%, while the benchmark Sensex has declined by 0.69%. Over the past month, Influx Healthtech has surged by 26.96%, contrasting sharply with the Sensex's modest gain of 1.70%. This strong performance relative to the benchmark suggests that investors are favoring Influx Healthtech over other options in the market.<BR><BR>Furthermore, the stock is trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which is typically a bullish signal. However, it is worth noting that there has been a decline in investor participation, with delivery volume falling by 37.9% against the 5-day average, which could indicate a potential concern for sustained momentum. Despite this, the overall indicators point towards a rising stock price for Influx Healthtech Ltd.